Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Interest Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Interest Expenses for 15 consecutive years, with $548000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Interest Expenses rose 1511.76% to $548000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $605000.0, a 177.52% increase, with the full-year FY2024 number at $179000.0, down 54.68% from a year prior.
  • Interest Expenses was $548000.0 for Q1 2025 at Plus Therapeutics, up from $57000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $548000.0 in Q1 2025 to a low of $27000.0 in Q2 2024.
  • A 5-year average of $154375.0 and a median of $130000.0 in 2022 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: tumbled 75.89% in 2024, then soared 1511.76% in 2025.
  • Plus Therapeutics' Interest Expenses stood at $200000.0 in 2021, then dropped by 26.0% to $148000.0 in 2022, then tumbled by 35.14% to $96000.0 in 2023, then crashed by 40.62% to $57000.0 in 2024, then soared by 861.4% to $548000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Interest Expenses are $548000.0 (Q1 2025), $57000.0 (Q4 2024), and $61000.0 (Q3 2024).